Does tirzepatide lower hemoglobin A1c?
Yes. Tirzepatide produces some of the largest A1c reductions seen with any non-insulin therapy — frequently 1.5–2.5 percentage points in patients with type 2 diabetes — through combined GLP-1 and GIP receptor activation plus substantial weight loss.
Full answer
Yes. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and in the SURPASS trial program it produced some of the largest hemoglobin A1c reductions seen with any non-insulin therapy — frequently 1.5–2.5 percentage points in patients with type 2 diabetes, depending on dose and baseline A1c. The mechanism stacks: GLP-1 activation improves glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite; GIP activation augments the insulin response and contributes to greater weight loss. The combined effect produces meaningful improvements in fasting glucose, post-prandial excursions, and A1c — typically alongside double-digit-percentage weight loss. As with all GLP-1 / GIP therapy, candidacy, dose escalation, side-effect management, and muscle preservation are provider-reviewed.
Educational. Not a substitute for individualized provider review.
- Tirzepatide — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29